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Interleukin-32: A Cytokine and Inducer of TNF
(Aksentijevich et al., 2002; Hawkins et al., 2004) reducesSoo-Hyun Kim,1,* Sun-Young Han,1 Tania Azam,1
Do-Young Yoon,2 and Charles A. Dinarello1 the signs and symptoms of these diseases as well as
1Department of Medicine the immunological and biochemical markers of inflam-
University of Colorado Health Sciences Center mation. Blocking IL-18 in animal models of disease has
Denver, Colorado 80262 reduced disease severity, including arthritis (Banda et
2Korea Research Institute of Bioscience al., 2003; Plater-Zyberk et al., 2001), inflammatory bowel
and Biotechnology disease (Siegmund et al., 2004), graft versus host dis-
Yuseong Daejon 305-600 ease (Min et al., 2004), ischemia-reperfusion injury (Pom-
South Korea erantz et al., 2001), and spontaneous atherosclerosis
(Mallat et al., 2001). Therefore, IL-18-inducible genes
might contribute to autoimmune and inflammatory dis-
Summary eases. However, there is an obstacle to studying IL-18-
inducible genes because IL-18 activity often requires
We describe the gene structure, regulation, signal costimulatory factors, such as IL-2, IL-12, or IL-15, in
transduction. and functions of a cytokine, interleukin order to manifest its responsiveness (Ahn et al., 1997;
(IL)-32. An IL-18 unresponsive cell was converted to Hoshino et al., 1999; Lauwerys et al., 2000; Ohtsuki et
a responsive cell by transfection of the IL-18 receptor al., 1997). This requirement of costimulatory factors pre-
 chain, and IL-18-induced microarray revealed high vents an independent assessment of solely IL-18-induc-
expression of a cytokine-like gene. Although IL-32 ible genes.
does not share sequence homology with known cyto- IL-18 has two known receptor chains, a ligand binding
kine families, IL-32 induces various cytokines, human IL-18R chain and a signal-transducing IL-18R chain.
TNF, and IL-8 in THP-1 monocytic cells as well as Both chains of the IL-18 receptor belong to the IL-1
mouse TNF and MIP-2 in Raw macrophage cells. IL- receptor family and consist of three Ig-like domains in
32 activates typical cytokine signal pathways of nu- the extracellular region (Kato et al., 2003; Yamamoto et
clear factor-kappa B (NF-B) and p38 mitogen-acti- al., 2004). An additional component of IL-18 complex is
vated protein kinase. IL-32 mRNA is highly expressed
IL-18 binding protein (IL-18BP), which is not a part of
in immune tissue rather than other tissues. Human IL-
the IL-18 signaling complex but, rather, binds and neu-
32 exists as four splice variants, and IL-32 from other
tralizes IL-18 activity (Kim et al., 2000; Novick et al.,
specieswere found as expressed sequence tag clones
1999). IL-18BP is a secreted receptor-like molecule,in the databank. Induced in human peripheral lympho-
which consists of a single Ig-like domain. IL-18BPcyte cells after mitogen stimulation, in human epithe-
shares a significant homology with viral proteins, whichlial cells by IFN, and in NK cells after exposure to the
neutralize the biological activities of human IL-18 (Es-combination of IL-12 plus IL-18, IL-32 may play a role
teban and Buller, 2004; Esteban et al., 2004; Readingin inflammatory/autoimmune diseases.
and Smith, 2003; Xiang and Moss, 1999).
In the absence of costimulants, nonimmune cells doIntroduction
not respond to IL-18 due to a low level or absence of
IL-18R chain (Chandrasekar et al., 2003). Therefore, itIL-18 is a multifunctional cytokine having roles in both
was necessary to generate a stable clone expressing theinnate and adaptive immune responses. IL-18 has been
IL-18R chain, an IL-18 receptor component required forstudied for its effects in the broad spectrum of Th1-
transmitting an IL-18 signal (Azam et al., 2003; Debetsor Th2-related autoimmune diseases (Nakanishi et al.,
et al., 2000; Kim et al., 2001b). Stable expression of the2001; Okamura et al., 1995, 1998). IL-1 and IL-18 belong
IL-18R chain was accomplished in the human lungto the IL-1 ligand family because they share structural
carcinoma A549 cell (A549-R), which converted thesesimilarity and require caspase-1 for processing (Bazan
cells to IL-18-responsive cells in the absence of a costi-et al., 1996; Gu et al., 1997). IL-18 also uses a similar
mulant. The A549-R stable clone was used for IL-18-signaling pathway as that of IL-1 family members. They
inducible genes with microarrays independent of costi-both recruit IL-1 receptor-associated kinases (IRAKs),
mulants. The IL-18-induced microarray study revealedform IRAK complexes with the tumor necrosis factor
the induction of a cytokine-like molecule, which was(TNF) receptor-associated factor-6, and activate the
described 12 years ago as natural killer cell transcriptcascade of inhibitor of kappa B/nuclear factor-kappa B
4 (NK4) (Dahl et al., 1992). Recently, increased gene(IkBa/NF-kB). (Kojima et al., 1998; Matsumoto et al.,
expression of NK4 has been reported in peripheral blood1997; Robinson et al., 1997).
mononuclear cells (PBMC) from patients receiving high-Members of the IL-1 ligand family play pathological
roles in autoimmune and inflammatory diseases (Dina- dose IL-2 therapy for malignant melanoma (Panelli et
rello, 2004). Blocking IL-1 in humans with rheumatoid al., 2002), but the function ofNK4has remainedunknown
arthritis (Bresnihan et al., 1998), ankylosing spondylitis until the present study. We demonstrate here that NK4
(Haibel et al., 2005), and mutations in the NALP3 gene is an inflammatory cytokine (IL-32) and describe its bio-
logical function, regulation of production, genomic
structure, and signal transduction.*Correspondence: soohyun.kim@uchsc.edu
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Figure 1. The Reconstitution of Functional IL-18R Chain in A549 Human Lung Carcinoma Cells and Microarray Study
(A) Human IL-18R expression in A549 cells. RT-PCR of IL-18R in the A549 cell line (A549-R).
(B and C) Stable clone (A549-R) was tested for the induction of IL-6 and IL-8 after IL-18 (50 ng/ml) stimulation for 16 hr (n  7).
(D) IL-18-inducible cytokine-related genes by microarray. A549-R cells were stimulated with IL-18 (50 ng/ml) for 6 hr then subjected for
microarray analysis. The figure shows that only cytokine-related genes were induced over 3-fold (log base 2) and added the new nomenclature
of cytokines (Bacon et al., 2002). The data present two independent experiments.
(E) The induction of NK4 in the same RNA used for IL-18-inducible gene microarray analysis.
Results al., 1992), and yet no functional data exist on this gene
product. The NK4mRNAwas examined by RT-PCRwith
the same RNA used for the microarray study. The tran-Identification of the Cytokine
Although the human lung carcinoma A549 cell line script of NK4 was detected only in IL-18-treated A549-
R cells and not in unstimulated A549-R cells (Fig-(A549-WT) expresses the endogenous IL-18 receptor 
chain, the IL-18 receptor  chain is not expressed as ure 1E).
We next examined the NK4 gene expression in thedetermined by RT-PCR (Figure 1A). After transfection
of IL-18R in A549 (A549-R), A549-R responded to human NK cell line (Hoshino et al., 1999) because the
NK4 gene was described as a NK cell product. The NK4IL-18 in the absence of a costimulus and produced IL-6
(Figure 1B) as well as IL-8 (Figure 1C), whereas the A549 gene was constitutively and highly expressed in this
cell line, which is maintained in conditioned mediumparent cell line (A549-WT) remained unresponsive to IL-
18. The A549-R stable clone was used to study IL-18- containing both IL-2 and IL-15. The presence of IL-2 in
the conditioned medium likely contributes to the highinducible genes by microarray, which revealed that IL-
18 induced several cytokine genes including IL-6 and level of NK4 gene expression (data not shown).
Because the biological function(s) of NK4 has re-IL-8 (Figure 1D). Among IL-18-inducible genes, which
were greater than 3-fold (log base 2), there were several mained unknown, the RT-PCR product of NK4 gene
was cloned for the purpose of producing a recombinantchemokines, IL-1, and granulocyte colony-stimulating
factor, each known as an IL-18-inducible gene. How- protein and to examine its biological activities. The re-
combinant NK4 protein was purified by using three se-ever, NK4was highly inducedat 5.3-fold (log base2). The
NK4 gene was first described 12 years ago (accession quential steps: His6-tag affinity, size exclusion, and ion
exchange chromatography. This process yielded a ho-numbers MN-004221 and AB007827) as a transcript in
IL-2-activated NK or mitogen-stimulated T cells (Dahl et mogenous band (Figure 2, top). The Raw 264.7 macro-
Interleukin-32: A TNF-Inducing Factor
133
databank, and the blast program revealed an expressed
sequence tag (EST) clone of equine, bovine, ovine, and
swine IL-32. The equine IL-32 (AC: CD469554 and
BI961524) shares the highest homology with human
(31.8% identity) followed by bovine (AC: CK832489),
ovine (AC: CO202364), and swine (AC: CB287292);
mouseESTcloneswere not available. Themultiple align-
ments present three species of IL-32 human, equine,
and bovine (Figure 3C). The ovine and swine have only
isoform A. Equine has isoform A (AC: CD469554) and
B, whereas bovine has isoform B and C. The sequence
of equine IL-32 or bovine IL-32 was combined in two
EST clones: CD469554 and BI961524 for equine IL-32
or CK834399 and CK832489 for bovine IL-32. The open
reading frame of equine IL-32 or bovine IL-32 was
deduced from the combined sequence.
The Biological Activity of rIL-32 and Antibody
Neutralization Assay
IL-32 induced significant amounts of TNF and MIP-2
and increased the production of both cytokines in aFigure 2. The Biological Activities of Recombinant IL-32 in Macro-
dose-dependentmanner (Figure 4A).We next comparedphage Raw 264.7 Cells
the biological activity of IL-32with that of IL-32, whichThe three steppurified recombinant IL-32wasexamined for biolog-
has a full C terminus. IL-32 induced similar levels ofical activity measuring the induction of TNF. The E. coli recombi-
TNF and MIP-2, as did IL-32 in the mouse macro-nant IL-32 induced TNF from Raw cells. The data represent
mean SEMof five separate experiments. Each ion exchange chro- phage Raw cell line (Figure 4B). Although experiments
matograph fraction is shown after 10% SDS-PAGE with Coomassie were performed in the presence of polymyxin B (5
blue staining in the upper panel. g/ml), we cannot rule out endotoxin contamination in
recombinant proteins from E. coli. Therefore, we pro-
duced recombinant IL-32 in mammalian cells. The rIL-phage cell line responded to stimulation of recombinant
32was produced from three different sources of mam-NK4 and produced large amounts of TNF (Figure 2,
malian cells: a stable clone of Anjou65 (a derivative ofbottom), which coincided with the peak fractions of pro-
the human epithelial 293T cell line), Cos7 stable clonetein eluting from ion exchange chromatography. At this
(Cos7-S), and Cos7 transient transfection (Cos7-T). Thepoint, we recognized that the recombinant NK4 protein
maximum yield of mammalian rIL-32 in supernatantspossesses a typical cytokine activity and renamed the
was as low as 1 ng/ml, and IL-32was below 100 pg/ml.molecule as IL-32.
Therefore, each mammalian rIL-32 was purified with
an immobilized anti-IL-32monoclonal antibody affinity
Genomic Structure of IL-32 and IL-32
column in the presence of sodium azide (0.02%) to pre-
from Other Species vent microbial growth during purification. Each of the
The genomic structure of IL-32 and its localization in three mammalian rIL-32 induced both human and
human chromosomeswere analyzed. The blast program mouse TNF in PMA-differentiated THP-1 cells and
in the NCBI gene databank revealed that IL-32 resides in mouse Raw cells, respectively (Figure 4C). E. coli rIL-
the human chromosome 16 p13.3. IL-32 has four splice 32 and mammalian rIL-32 increased human TNF
variants due to mRNA splicing, as shown in Figure 3A. (Figure 4D) and human IL-8 production (data not shown)
Three splice variants, IL-32, IL-32, and IL-32, were in PMA-differentiated THP-1 cells in a dose-dependent
isolated from human NK cells by RT-PCR, whereas the manner. Furthermore, the high concentrations of E. coli
IL-32 variant was previously reported as the NK4 tran- rIL-32 and mammalian rIL-32 of Anjou65 induced hu-
script. IL-32 is organized with eight small exons; the man IL-8 in nondifferentiated THP-1 cells, but superna-
second exon contains an ATG codon. IL-32 has an tant of affinity-purified mock-transfected Anjou65 did
additional 46 amino acids in the N terminus because not induce IL-8 (Figure 4E).
of the absence splicing between exon 3 and exon 4. The affinity-purified monoclonal antibody (mAb; 32-4)
However, in IL-32 the second exon is absent, which against rIL-32 resulted in a high background level of
results in a shift ATGcodon in the third exon.Because IL- mTNF. Therefore, we generated the Fab fragment of
32 is the most abundant cDNA clone, the recombinant the mAb. The background level was reduced dramati-
protein of this isoform was used for the experiments. cally after removing the Fc fragment. We assessed neu-
IL-32 has a deletion of 57 amino acid residues in the tralizing rIL-32 and rIL-32 activitieswith the FabmAb.
C terminus (Figure 3B) due to the splicing of exons 7 Figure 4F depicts Fab mAb (50 ng/ml) reduction in the
and 8, in contrast to the other splice variants, which biological activity of E. coli rIL-32 of more than 70%
have a large single exon at the end. The analysis of in a dose-dependent manner. In addition, the same Fab
the IL-32 amino acid sequence revealed three potential inhibited the affinity-purified rIL-32 Cos7-S activity by
N-myristoylation sites and one N-glycosylation site that greater than 65% (Figure 4G). A higher concentration
are indicated (Figure 3B). of Fab mAb did not reduce further IL-32 activities in
these assays.We searched for other species of IL-32 in the NCBI
Immunity
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Figure 3. The Genomic Organization of Four IL-32 Splice Variants and Other Species of IL-32 by Amino Acid Sequence Alignment
(A) IL-32 resides in human chromosome 16p13.3. The four IL-32 splice variants cDNA sequences were aligned with the 5 kb genomic sequence.
(B) The multiple alignments present four human IL-32 splice variants. A potential posttranslational modification site was analyzed (http://
ca.expasy.org), and Myr or Gly indicates three potential N-myristoylation or one N-glycosylation site, respectively.
(C) The alignment exhibits three IL-32 species: human, equine, and bovine. The consensus amino acid residue was shown at bottom of the each
line. The alignment has been done by using the LALIGN program (www.ch.embnet.org/software/LALIGN_form.html) and manually corrected.
Expression of IL-32 mRNA and IL-32 Protein N-glycosylation and three N-myristolation sites as indi-
cated (Figure 3B).We analyzed the expression of IL-32 in various human
tissues by Northern blot. The 1.2 kb IL-32 transcript was We further examined the induction of IL-32 in human
epithelial Wish cells treated with IFN because the Wishdetected in several tissues, but IL-32 expression was
more prominent in immune cells than in nonimmune cells are commonly used for antiviral assay and other
biological activities of IFN. As shown in Figure 5C, IL-tissues (Figure 5A). The high expression of IL-32 mRNA
in immune tissues is not due to a difference in the 32 was induced in cell lysates of human epithelial cells
in a time-dependent manner and diminished after 46 hr,amount of mRNA in each lane.
Endogenous expression of IL-32 was also detected whereas IL-32 was not induced in unstimulated cells.
IL-18 and IL-1 increased the expressionof endogenousat the protein level. A549-R cells were treated with
either IL-18 or IL-1 as indicated (Figure 5B). Endoge- IL-32 in the lysates of A549-R cells in a time-dependent
manner (Figure 5D), whereas IL-32 was induced by onlynous IL-32 (27 kDa) was detected by immunoblot by
using affinity-purified rabbit anti-human IL-32 poly- IL-1 in A549-WT (Figure 5E), similar to IL-6 and IL-8
products from this cell line (Figures 1B and 1C). In addi-clonal antibody. Although IL-32 does not possess a typi-
cal hydrophobic signal peptide in its N terminus, IL-32 tion, we observed IFN-induced IL-32 in the lysate of
A549-WT (data not shown).was detected as a secreted molecule. By Western blot
analysis, IL-32 was present in the culture medium of It was next determined whether the recombinant pro-
teins from the cDNA of IL-32 and IL-32 expression inA549-R cells after 48 hr of stimulation in the presence
of IL-18 or IL-1, but there was no synthesis in unstimu- mammalian cells were comparable to endogenous IL-
32. Cos7 cells were transiently transfected with IL-32lated cells. A difference in molecular weight between
the recombinant IL-32 from E. coli (right lane of Figure and IL-32 cDNAs. Both cell culture media and lysates
were used to detect the recombinant IL-32 by immu-5B) and endogenous IL-32 may be due to posttransla-
tional modifications. For example, the amino acid se- noblot or quantified by using a specific ECL assay. IL-
32 and IL-32were present in the culturemedia (Figurequence analysis revealed that IL-32 has one potential
Interleukin-32: A TNF-Inducing Factor
135
Figure 4. Biological Activities of rIL-32 and Fab Monoclonal (32-4) Antibody Neutralization Assay
The rIL-32 induces proinflammatory cytokines in macrophage Raw and human monocytes THP-1 cells.
(A) Dose-dependent E. coli derived IL-32-induced TNF and MIP-2. IL-32 concentrations are indicated in units/ml on the horizontal axis.
(B) Both IL-32 (10 U/ml) and IL-32 (10 U/ml) variants are active in Raw cells.
(C) Human and mouse TNF induced by various sources of mammalian IL-32. Raw and PMA-differentiated THP-1 cells were treated with
1 U/ml of Anjou65 and Cos7-S, or 2 U/ml of Cos7-T.
(D) Dose-dependent E. coli IL-32 and mammalian IL-32 (Cos7-T) induced human TNF in PMA-differentiated THP-1 cells. The units are
indicated at the bottom of the graph.
(E) The high concentrations of E. coli rIL-32 (20 U/ml) or mammalian rIL-32 (Anjou65, 10 U/ml) induced human IL-8 in nondifferentiated
THP-1 cells.
(F) Dose-dependent Fab mAb neutralization of E. coli rIL-32 (3 U/ml). The Fab concentration is indicated at the bottom of the graph.
(G) Mammalian rIL-32 (Cos7-S, 2 U/ml)-induced mTNF is shown in the presence of Fab mAb (40 ng/ml). The data represent mean  SEM
of three separate experiments.
5F) and lysates (Figure 5G). Themolecular size of recom- activity, we stimulated NK cells in the presence of a
neutralizing anti-huIFN (Choi et al., 2001), and therebinant mammalian IL-32 in the immunoblot is identical
in molecular size to the endogenous IL-32 shown in was no effect on IL-32 induction (data not shown).
Human PBMC contain mostly T cells with fewer num-Figure 5B. The ECL assay revealed similar distribution
of IL-32 and IL-32 in the same culture media and bers of monocytes and B cells. Freshly prepared PBMC
were stimulatedwith LPSorConA, and the supernatantslysates. IL-32 was more efficiently secreted compared
to IL-32, which was mostly associated with the cell and lysates were assayed for level of IL-32. After 60 hr,
there was no detectable IL-32 in the supernatants or(Figure 5H).
lysates of PBMC stimulated with LPS (data not shown).
However, Con A consistently induced IL-32, which wasProduction of IL-32 in NK Cells and Primary PBMC
found in the supernatants and lysates primarily after 60To determine the regulation of IL-32 production, we ex-
hr. The lysates contained more IL-32 than the superna-amined different cell lines as well as human PBMC. IL-
tants (Figure 6C).32 was detected in the cell culture medium of A549-R
We further examined Con A-induced TNF in humanafter IL-18 or IL-1 stimulation, but not in control me-
PBMC through IL-32. Freshly isolated PBMC were stim-dium (Figure 6A). Because the NK4 (IL-32) gene was
ulated with Con A in the presence of various concentra-isolated from IL-2-activated NK cells, we stimulated the
tions of the same Fab anti-IL-32 that neutralized thehuman NK cell line with the combination of IL-12 plus
biological activity of rIL-32 (Figures 4F and 4G), but thereIL-18. As shown in Figure 6B, there was a significant
was no effect on Con A-induced TNF or IFN produc-induction of IL-32 by IL-12 or IL-18. The effect of the
tion (data not shown).combination of these two cytokines appeared additive.
By comparison, when this cell line is stimulated by either
IL-12 or IL-18, there is little or no induction of IFN, Signal Transduction of IL-32
Signal transduction of the cytokine IL-32 was also stud-whereas IFN production by the combination of IL-12
plus IL-18 is highly synergistic (Kim et al., 2002). To ied. The degradation I	B was examined because IL-32
induced TNF and MIP2, two cytokines known to beexamine the induction of IL-32 as a function of IFN
Immunity
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Figure 5. The Expression and Regulation of IL-32
Endogenous expression of IL-32 at both mRNA and protein levels.
(A) The Northern blot depicts the expression of IL-32 mRNA in various human tissues as listed in each lane. The numbers on the most left
lane indicate the size of mRNA and the /Northern blot.
(B) The detection of released endogenous IL-32 in the cell culture supernatant. The A549-R stable clone was stimulated for 48 hr in the
presence of the following stimuli, IL-18 (50 ng/ml) or IL-1 (10 ng/ml) as indicated. The supernatants were harvested then probed with the
affinity-purified anti-IL-32 antibody.
(C–E) The detection of IL-32 in cell lysates at various times as indicated. (C) Human Wish cells were stimulated with IFN (100 U/ml) or (D) A549-
R, and (E) A549-WT cells were stimulated with IL-18 (50 ng/ml) or IL-1 (10 ng/ml). The data represent one of three independent experiments.
(F and G) IL-32 and  cDNA were transiently transfected into Cos7 cells. After 20 hr of transfection, immunoblot or electrochemiluminescence
(ECL) analysis of cell culture supernatants and lysates. (F) Cell culture supernatants and (G) lysates were subjected for immunoblot with anti-
IL-32 antibody.
(H) ECL measured IL-32 concentration in the same supernatants and lysates. The data represent mean  SEM of five separate experiments.
activated by NF-	B. As shown in Figure 7A, IL-32 in- production, signal transduction, and function of IL-32
duced I	B degradation in a time-dependent manner, are described. IL-32 was deposited in the databank 12
beginning 15min after exposure and reaching amaximal years ago asNK4, a transcript of activated humanT cells
level at 45 min followed by recovery after 90 min. The and NK cells after stimulation by mitogens or IL-2, re-
phosphorylation of p38 MAPK, another characteristic spectively (Dahl et al., 1992). It should be noted that the
of the inflammatory cytokine signal pathway, was also term NK4 is presently used to describe a variant of
studied. Phosph-p38 MAPKwas dramatically increased hepatocyte growth factor (Martin et al., 2002). There is
5 min after stimulation by IL-32 and then decreased no sequence homology between the hepatocyte growth
from 15 to 30 min thereafter (Figure 7B). Interestingly, factor variant and NK4/IL-32. Although IL-32 lacks se-
a second increase in p38 MAPK phosphorylation was quence homology to the presently known cytokine fami-
observed at 45 min and then decreased slowly. lies, its ability to induce the proinflammatory cytokines
such as TNF, IL-8, and MIP-2 in different cells and to
signal through the classical signal pathways of proin-Discussion
flammatory cytokines places the gene in the class with
other cytokines.In the present study, we add a cytokine, which we have
The discovery of IL-32 as a cytokine was carried outtermed IL-32, to the growing number of molecules with
with the specific goal of understanding IL-18-induciblefunctions for both innate and acquired immune systems.
The gene structure, splice variants, tissue distribution, genes in the absence of costimulants. Therefore, we
Interleukin-32: A TNF-Inducing Factor
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Figure 6. The Measurement of Endogenous IL-32 by ECL
(A) IL-32 was detected by ECL assay with the same samples that were used for the immunoblot of Figure 5B.
(B) IL-12, IL-18, or IL-12 plus IL-18 induced IL-32 in the supernatant of human NK cell line. The data represent mean  SEM of four
separate experiments.
(C) Con A-induced IL-32 was detected in both supernatants and lysates of human PBMC (n  7).
designed an IL-18-responsive cell line (A549-R) and monocytic THP-1 cells, which may implicate a specific
IL-32 receptor expression only in these differentiatedsubjected the IL-18-stimulated mRNA for gene chip
cells. The high concentrations of E. coli rIL-32 andanalysis. Several of the transcripts increased by IL-18
mammalian rIL-32 provoked a weak response in non-were not unexpected, but NK4 was induced to a rela-
differentiated THP-1 cells (Figure 4E). High concentra-tively high level and was without known function. There-
tions of bothE. coli andmammalian rIL-32did not inducefore, the first approach was to express the molecule
cytokines in freshly obtained human PBMC, further sup-and examine the function(s) of the recombinant protein.
porting the observation that biological activity of rIL-32The homogenous protein peak eluting from the purifica-
is not due to endotoxin contamination.tion coincided with the induction of TNF by macro-
We tested two mAbs (clones 32-4 and 32-9) againstphages (Figure 2). IL-32 triggered the typical cytokine
E. coli rIL-32, and both antibodies inhibited IL-32 activ-signal pathways of NF	B and p38 MAPK and also in-
ity about 30% (data not shown). However, the high con-duced TNF and chemokines. This is a demonstration
centration of both mAbs induced mTNF, which is un-of a biological function and signaling transduction of IL-
usual because the same species of mAb that stimulate32 as that of a typical proinflammatory cytokine.
mouse Raw cells do not often also result in TNFa induc-We produced mammalian rIL-32 from different
tion. Therefore the Fab fragment of mAb (32-4) was pre-sources. The mammalian rIL-32 induced human and
pared and used for neutralization assay. The Fabmono-mouse TNF in PMA-differentiated human monocytic
clonal antibody neutralized 75% of IL-32 biologicalTHP-1 cells and mouse Raw cells. Affinity-purified su-
activity in mouse Raw cells (Figure 4F), and a similarpernatant from mock-transfected cells did not induce
result was observedwithMIP-2 in the same assays (dataTNF (Figure 4C). IL-32 is active on highly differentiated
not shown).cells such as mouse macrophage Raw and human
The original description of NK4 was reported in IL-2
and mitogen-activated NK or T cells. In the present
study, we found that IL-32 is expressed constitutively
in various organs (Figure 5A), which is similar to IL-15.
IL-15 is produced by a wide variety of tissues, whereas
IL-2 is exclusively produced by activated T cells (Bam-
ford et al., 1996; Grabstein et al., 1994). The induction
of IL-32 in either immune or nonimmune cells may be
an important property for the cytokine (Figure 5). We
have detected elevated levels of IL-32 in circulation of
some, but not all, patients with sepsis compared to
healthy individuals (data not shown), but this finding is
not unexpected and is rather consistent with several cy-
tokines.
The secretion of IL-32 in the absence of a clear signal
peptide is characteristic of several cytokine families
(Cerretti et al., 1992; Ghayur et al., 1997; Kuida et al.,
Figure 7. IL-32-Induced I	B Degradation and Phosphorylation of 1995). Similar to IL-1 and IL-18, IL-32 is secreted as a
p38 MAPK soluble protein in cell culture media of stimulated pri-
Raw cells were stimulated with IL-32 (20 U/ml) at the indicated mary cells as well as cell lines (Figures 5 and 6). IL-32
times.
does not possess potential caspase-1 cleavage sites(A) The membrane was probed with rabbit anti-IkB and then normal-
by primary sequence analysis. New splice variants haveized with goat anti-actin.
been found, and none of the IL-32 splice variants pos-(B) The membrane was probed with rabbit anti-phospho-p38 MAPK
and then normalized with rabbit anti-p38 MAPK. sess a typical hydrophobic signal peptide at the N termi-
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nus. IL-32 isoform was sufficiently secreted to cell cul- nent source of the cytokine. Human peripheral T cells
ture supernatant by transient transfection into Cos7 cell, stimulated with Con A are a source of TNF (Brod et al.,
though no signal peptide exists at the N terminus. It 1996; Chang and Shaio, 1995), but the link of mitogen-
remains unclear how IL-32 is secreted from stimu- activated CD4
 T cells by Con A is best found in an
lated cells. animal model of Con A-induced hepatitis (Kusters et al.,
The existence of IL-32 in other species is evidence 1997; Tiegs et al., 1992). In that model, either IL-18 or
of an evolutionarily conserved molecule that may have TNF neutralization prevents the development of the
important functions in immune responses (Figure 3C). disease (Fantuzzi et al., 2003; Tiegs et al., 1992). It is
Not as many IL-32 isoforms are found in other species possible that Con A-induced TNF involves IL-32 and
as in the human because in other species, the EST data- is based on the ability of Con A-stimulated CD4
 T cells
bank is not sequenced as extensively as in the human. to mediate the hepatitis (Tiegs et al., 1992) and to pro-
Alternatively, they do not exist as in the case of human duce IL-32. IL-32, in turn, would activate macrophagic
IL-18BP, which exists as four isoforms, whereas mouse Kupffer cells to release TNF and cause hepatocyte cell
has only two isoforms (Kim et al., 2000; Novick et al., death. Such a mechanism is supported by the findings
1999). Intensive searching for a mouse IL-32 homolog in the present paper that recombinant IL-32 induced
with various IL-32 species did not reveal amouse homol- TNF from differentiated macrophages.
ogous gene. It is possible that a mouse IL-32 gene has Although several immune regulatory molecules have
very low homology with human because equine or bo- beendiscovered during thepast decade,manyphenom-
vine shares only 31.8%–28.1% identities, respectively, ena remain unexplained in understanding immune regu-
with human IL-32, which is contrary to other cases of lation. The functional portfolio of the cytokine IL-32 may
evolutionary well-conserved genes. help unravel the complexity of cytokine biology. The
After transient transfection into Cos7 cells, IL-32 iso- identification of IL-32 receptor components, functional
form remained inside the cell unlike IL-32 (Figure 5H). characterization of the different splice variants, and
Also, IL-32 was detected in cell lysates after stimulation analysis of the variation of IL-32 expression in diseases
(Figures 5C–5E). Therefore, we cannot exclude the pos- will contribute to understanding a precise role of IL-32
sibility of an intracellular function for IL-32. There are in the network of cytokine biology.
examples of such functions; cytokines such as IL-1
(Stevenson et al., 1997) and highmobility group-1 (Wang Experimental Procedures
et al., 1999) are active as intracellular aswell as extracel-
Stable Expression of IL-18R Chain in A549lular proteins (Werman et al., 2004).
Human lung carcinoma A549 cells (3  105 per well) were seededSplice variants are unusual in cytokine genes; never-
in a 6-well plate a day before transfection. The cells were washedtheless, splice variants exist in cytokines such as IL-15,
with 2 ml of Opti-MEM (Invitrogen, Carlsbad, CA) and incubated for
IL-1F7, and VEGF (Bufler et al., 2002; Kumar et al., 2002; 25 min in 1 ml of the same medium prior to transfection. In the
Meazza et al., 1996; Nishimura et al., 1998; Pufe et al., meantime transfection mixture solution for each well was prepared
2001). IL-15 exists as two isoforms, a long signal peptide as follows. We mixed 5 l of Lipofectamine 2000 in 100 l of Opti-
MEM and then incubated the mixture for 5 min in a hood. Next, 2 g(48 amino acids) and a short signal peptide (21 amino
of plasmid DNA, pTARGET/huIL-18R (Kim et al., 2001b) was addedacids) due to an alternative splicing in exon 5 (Tagaya
and incubated for 20 min. The transfection mixture solution waset al., 1997). Although both IL-15 isoforms possess iden-
added to a well, and the plate was incubated for an additional 4
tical biological properties, sharing the same receptors hr in a cell culture incubator. Adding 2 ml of cell culture medium
and biological functions, each IL-15 isoform has a dis- containing 10% FCS in each well terminated the transfection. The
tinct regulation and expression pattern. The long signal next day, cells were trypsinized and transferred in a plate (15 cm).
peptide IL-15 isoform is more efficiently secreted in su- After cells adhered to the plate, the culture medium was replaced
with fresh medium containing 800 g/ml of Neomycin (G-418, In-pernatant (Tagaya et al., 1997), which is similar to the
vitrogen). The selection medium was exchanged every 3 days withIL-32 isoform.
fresh selection medium until individual colonies appeared, whichInflammatory cytokines, such as IL-1, IL-18, and
took place between 10 and 14 days. Small pieces of circular 3 MM
IFN, induced IL-32 from two different epithelial cell papers were sterilized andwet with trypsin and then used for picking
types (Figures 5B–E), a common target in several inflam- individual colonies. Colonies were transferred into 24-well plates
matory diseases. Moreover, most members of the vari- containing 1ml of selectionmedium in eachwell. An individual clone
was grown until the cells reached a population of 106, and eachous cytokine families induce each other, and this also
clone was tested for the RT-PCR of transfected gene IL-18R asserved as part of the rationale for renaming the NK4
well as for bioassays measuring IL-6 and IL-8 in cell culture mediumtranscript as IL-32. In addition, IFN induces IL-32 in a
after IL-18 stimulation for 24 hr. Three clones were positive in bothtime-dependent manner (Figure 5C), suggesting a role
the RT-PCR of IL-18R and bioassays. Limiting dilutions in order
for IL-32 in innate and adaptive immune responses. The to obtain a single clone cultured these clones. A single clone used
induction of TNF by IL-32 suggests that IL-32 has an for this study is one of the subclones from the limiting dilution.
important role in autoimmune/inflammatory diseases
because blockade of TNF activity is a highly effective Cells and Bioassays
therapeutic approach in rheumatoid arthritis (Firestein, Human NK cell line was obtained from Dr. Hans Klingerman (Rush
Medical Center, Chicago, IL) and cultured in RPMI-1640 medium2003), Crohn’s disease (van Dullemen et al., 1995), and
containing 10% FCS, IL-2 (50 pg/ml), and IL-15 (200 pg/ml) (Pepro-psoriasis (Leonardi et al., 2003).
tech, Rocky Hill, NJ). Mouse macrophage Raw 264.7, human A549Similar to the original description of NK4, we observed
lung carcinoma, monkey kidney Cos7, Anjou65 (a derivative of the
that Con A induced IL-32 from freshly isolated human human epithelial 293T cell line), human epithelial Wish, and human
PBMC. However, in these same PBMC cultures, LPS monocytes THP-1 cell line were obtained from American Type Cul-
was without effect. It is unlikely that peripheral blood ture Collection (ATCC) and maintained according to ATCC instruc-
tions. Bioassays were performed in 96-well plates. Briefly, Raw cellsmonocytes triggered by Toll-like receptors is a promi-
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(5  105/ml, 0.1 ml/per well), A549-R cells (2  105/ml, 0.1 ml/per were subjected to ion-exchange chromatography (HiTrapQFF,
A¨KTAFPLC). The three step-purified recombinant proteins werewell), and human NK cells (5  105/ml, 0.1 ml/per well) were seeded
in 96-well plates and cultured until cells adhered to the plate. For tested for biological activities.
Raw cell assays, the medium was removed and then stimulated
with fresh medium (0.2 ml) containing various concentrations of IL- Expression of Mammalian Recombinant Proteins
32 in the presence 5 g/ml of polymyxin B (Bedford Laboratories, pTARGET/IL-32 containing His6-tag at the C terminus was tran-
Bedford, OH). For A549-R cells assays, the medium was removed siently transfected into Cos7 cells (8  106) with DEAE-Dextran as
and then stimulated with fresh medium (0.2 ml) containing IL-18, described (Kim et al., 2000; Novick et al., 1999). For stable clones,
which was produced as described (Kim et al., 2001a). For NK cell pTARGET/Mock and pTARGET/IL-32-his6 were transfected into
assays, cells were stimulated with IL-12 (Peprotech), IL-18, or both Cos7 cells (1  106) or Anjou65 cells (1  106) with Opti-MEM as
cytokines. THP-1 cells (5  105/ml, 0.1 ml/per well) were seeded in described above for the stable transfection of IL-18R. The transient
96-well plates in the absence of FCS and then stimulated with rIL- and stable clone cells were cultured in media (0.5% FCS) for 4
32s. For PMA-differentiated THP-1 assays, THP-1 cells (0.25  days then harvested for the next step of purification. The transient
105/ml, 0.1 ml/per well) were seeded in 24-well plates and stimulated transfection cell supernatants were purified as described for the
with 100 ng/ml of Phorbol 12-myristate 13-acetate (PMA, Sigma, St three-step purification of E. coli rIL-32. The stable clone supernatant
Louis, MO) for 48 hr. The plate was washed and left overnight in was purified with the affinity column of mAb anti-IL-32 immobilized
medium without FCS and then treated with rIL-32 in fresh medium. to agarose beads (Affi-Gel Hz, Bio-Rad) according tomanufacturer’s
The plates were placed in a cell culture incubator for 16–20 hr, and instruction. The purified IL-32 was dialyzed against RPMI containing
then the culture supernatants were collected for cytokine measure- penicillin/streptomycin at 4C prior to bioassay.
ments.
Human PBMC were isolated from residual leukocytes after plate- Immunization and Fusion
letpheresis of healthy donors with Histopaque (Sigma) and was A 5-week-old female Balb/c mouse was immunized with 20 g of
approved by Combined Colorado Investigational Review Board. rIL-32 antigen emulsified in Freund’s complete adjuvant (Sigma).
PBMC (1.5  107) were seeded in 6-well plates in 3 ml of RPMI On days 14 and 21, the mouse was given an intravenous and intra-
containing 10%FCS then stimulatedwith 20g/ml of Con A (Sigma). peritoneal injection with the antigen emulsified in Freund’s incom-
The plates were placed in a cell culture incubator for 60 hr. The plete adjuvant (Sigma). After three injections, the mouse was sacri-
culture supernatant and cell lysate were collected for IL-32 mea- ficed, the spleen was aseptically removed, and splenocytes were
surement. prepared for fusion. Briefly, 1  107 splenocytes and 1  106 NS-1
IL-32 units were established for the biological activity of IL-32 mouse myeloma cell line (ATCC) were fused by using polyethylene
because of differences between E. coli rIL-32 and mammalian rIL- glycol 1500 (Roche Applied Science, Indianapolis, IN). Fused cells
32. In addition, E. coli rIL-32 showed variations among different were resuspended at 1  106 cells/ml in hybridoma growth media
batches. One unit/ml of IL-32 is a 2-fold increase of mouse TNF with 10% FCS and HAT. Cells were then plated in 96-well plates.
in mouse Raw cells or of human TNF in PMA-differentiated THP-1 After 2 weeks, the culture supernatants of hybridomawere screened
cells. The conditions of assays are described above. Approximate with rIL-32 coated plates for direct ELISA. mAb classes and sub-
concentration of 1 unit for E. coli rIL-32 is 20 ng/ml (mammalian rIL- classes were determined by using an Immuno-TypeTM mouse mAb
32 is 2 ng/ml) as calculated by using ECL and Western blot. isotyping kit (BD Bioscience, San Diego, CA) according to themanu-
facturer’s instructions.
Microarray
A549-R cells were seeded at 2  106 in plates (9 cm) one day Production of Ascites and Purification of Antibodies
before the experiment. Cells were stimulated with IL-18 (50 ng/ml) Two hybridoma 32-4 (IgG1) and 32-9 (IgG1) clones (5  106 cells)
for 6 hr then total RNA was isolated with RNeasy kit (QIAGEN, were intraperitoneally injected into an 8 9-week-old female Balb/c
Valencia, CA) according to the manufacture’s instruction. Total RNA mouse. After a week, the ascites fluid was removed with a sterile
(10 mg/ml) was converted to first strand cDNA by using Superscript needle. Supernatants were collected by centrifugation, purified by
II RT (Invitrogen). The second-strand cDNA was synthesized with using protein A Sepharose (Bio-Rad), and eluted with 0.1 M glycine-
the use of T4 DNA polymerase I. After second-strand synthesis, the HCl, (pH 2.7).
reactionmixturewas cleanedwith a kit supplied byGeneChip. cRNA Immobilized IL-32 was also used to purify the Fab fragment of
synthesis was performed to generate biotin-labeled cRNAby using a mouse monoclonal antibody (32-4). Clarified ascites fluid was
RNA transcript-labeling kit. The biotinylated-cRNA was fragmented passed over the IL-32 ligand affinity column and eluted with 0.1 M
prior to hybridization. The samples were hybridized to the Affymetrix glycine-HCl, (pH 2.7). The affinity-purified antibody was incubated
GeneChip HG-U133, and data were analyzed in the microarray core with immobilized pepsin (Pierce, Rockford, IL) for 4 hr at 37C. The
laboratory of the University of Colorado Health Sciences Center. cleaved and noncleaved Fc products of digestion were then passed
over protein G Sepharose (Amersham, Bioscience, Sweden). The
Fab preparation was subjected to 7.5% SDS-PAGE to confirm ho-RT-PCR and Cloning for E. coli or Mammalian Vectors
mogeneity, and this preparation was used for neutralization.Total RNA was isolated with Tri-Reagent (Sigma, St Louis, MO) from
the human NK cells. A pair of sense primer, 5-CTGTCCCGAGTCTG
GACTTT-3, and reverse primer, 5-GCAAAGGTGGTGTCAGTATC- Northern Blot
3, were used for the RT-PCR. Superscript II RT (Invitrogen) con- The cDNA probe of both IL-32 and actin (Azam et al., 2003) were
verted 2 g of total RNA to first strand cDNA, and then PCR reaction excised from plasmid vectors by using restriction enzymes, then
was performed at 94C for 45 s, 70C for 2 min, and 59C for 1 min the inserts of cDNA were purified with GeneClean II kit (Q-BIO gene,
for 30 cycles. The PCR products were ligated into pGEMT-Easy Carlsbad, CA). The cDNA probes were 32P-dCTP-labeled (NEN Life
(Promega, Madison, WI) for DNA sequencing and then IL-32 inserts Science, Boston MA) by random priming and by using Klenow (New
were transferred into pPROEX/HTa (Invitrogen) for E. coli or pTAR- England Biolabs, Beverly, MA). A membrane containing human poly
GET (Promega) for mammalian expression. (A)
 RNA from different tissues (humanMTN Blot II, BD) was probed
with the cDNA probes and autoradiographed.
Expression of E. coli Recombinant Proteins
Recombinant IL-32 and IL-32 proteins were expressed in E. coli Immunoblots
For detection of IkB degradation and phosphorylation of p38MAPK,and purified by a TALON affinity column (Invitrogen) by using His6-
tag at the N terminus of recombinant proteins. The TALON affinity- Raw 264.7 macrophage cells were stimulated with IL-32 (20 U/ml)
in the presence of 5 g/ml polymyxin B (Bedford Lab) at variouspurified proteins were subjected to size exclusion chromatography
(Superdex 75, A¨KTAFPLC) and then digested with TEV (tobacco times. Cells were lysed with kinase lysis buffer (Han et al., 2002)
then subjected to 10% SDS-PAGE. The samples were transferredetch virus, Invitrogen) for 16 hr at 4C in order to remove the His6-
tag fusion protein. The TEV-cleaved recombinant proteins were to nitrocellulose membranes. The membranes were blocked in 3%
BSA (Santa Cruz Biotechnology, Santa Cruz, CA). The first mem-dialyzed in phosphate buffer (20 mM, [pH 9]). These materials
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brane was probed with rabbit anti-IkB (Santa Cruz Biotechnology) lymphotrophic virus type I region/IL-15 fusion message that lacks
many upstream AUGs that normally attenuates IL-15 mRNA transla-and then normalized with goat anti-actin (Santa Cruz Biotechnol-
ogy). The second membrane was probed with rabbit anti-phospho- tion. Proc. Natl. Acad. Sci. USA 93, 2897–2902.
p38 MAPK (Cell Signaling, Beverly, MA) and then normalized with Banda, N.K., Vondracek, A., Kraus, D., Dinarello, C.A., Kim, S.H.,
rabbit anti-p38 MAPK (Cell Signaling). Bendele, A., Senaldi, G., and Arend, W.P. (2003). Mechanisms of
For the detection of an endogenous IL-32, A549-R cells were inhibition of collagen-induced arthritis by murine IL-18 binding pro-
seeded at 106 cells per well in 6-well plates, and cell culture media tein. J. Immunol. 170, 2100–2105.
were exchanged after the cells had adhered. The cells were stimu-
Bazan, J.F., Timans, J.C., and Kastelein, R.A. (1996). A newly definedlated for 48 hr in the presence of the following stimuli, IL-18
interleukin-1? Nature 379, 591.(50 ng/ml) or IL-1 (10 ng/ml) in the absence of FCS. The superna-
Bresnihan, B., Alvaro-Gracia, J.M., Cobby, M., Doherty, M., Domljan,tants were harvested then concentrated ten times with Centricon
Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al.(YM-10, Life Sciences, Ann Arbor, MI) prior to detection of IL-32.
(1998). Treatment of rheumatoid arthritis with recombinant humanFor a time course of IL-32, Wish, A549-WT, or A549-R cells were
interleukin-1 receptor antagonist. Arthritis Rheum. 41, 2196–2204.seeded at 5  104 cells per well in 6-well plates for overnight and
then stimulated with IFN (100 U/ml, Peprotech), IL-18 (50 ng/ml), Brod, S.A., Marshall, G.D., Jr., Henninger, E.M., Sriram, S., Khan, M.,
or IL-1 (10 ng/ml). Affinity-purified rabbit anti-IL-32 was used for and Wolinsky, J.S. (1996). Interferon-beta 1b treatment decreases
detecting endogenous IL-32 in cell culture medium or lysate by tumor necrosis factor-alpha and increases interleukin-6 production
immunoblot. Peroxidase-conjugated secondary antibodies (Jack- in multiple sclerosis. Neurology 46, 1633–1638.
son ImmunoResearch Laboratories, West Grove, PA) were used
Bufler, P., Azam, T., Gamboni-Robertson, F., Reznikov, L.L., Kumar,
to develop the blots by using enhanced chemiluminescence (NEN
S., Dinarello, C.A., and Kim, S.H. (2002). A complex of the IL-1
Life Science).
homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity.
Proc. Natl. Acad. Sci. USA 99, 13723–13728.
Electrochemiluminescence
Cerretti, D.P., Kozlosky, C.J., Mosley, B., Nelson, N., Van Ness, K.,A polyclonal antibody produced in rabbits against recombinant IL-
Greenstreet, T.A., March, C.J., Kronheim, S.R., Druck, T., Canniz-32 was used for electrochemiluminescence (ECL). IgG was pre-
zaro, L.A., et al. (1992). Molecular cloning of the interleukin-1 betapared with Econo-Pac and then affinity purified through IL-32-
converting enzyme. Science 256, 97–100.immobilized agarose bead column of Affi-gel 15. An aliquot of the
Chandrasekar, B., Colston, J.T., de la Rosa, S.D., Rao, P.P., andaffinity purified anti-IL-32 antibody was labeled with biotin and
Freeman, G.L. (2003). TNF-alpha and H2O2 induce IL-18 and IL-another aliquot with ruthenium according to the manufacturer’s in-
18R beta expression in cardiomyocytes via NF-kappa B activation.structions (BioVeris, Gaithersburg, MD). The biotin, and ruthenium,
Biochem. Biophys. Res. Commun. 303, 1152–1158.labeled antibodies were used to construct a standard curve using
recombinant IL-32 for ECL assay. The liquid-phase ECL method Chang, F.Y., and Shaio,M.F. (1995). Decreased cell-mediated immu-
was used tomeasure TNF, IL-6, IL-8, IL-32, andMIP-2 in cell culture nity in patientswith non-insulin-dependent diabetesmellitus. Diabe-
media and serum samples. The amount of ECL was determined by tes Res. Clin. Pract. 28, 137–146.
using an Origen Analyzer (BioVeris).
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